CA
BMRN icon

Commerzbank Aktiengesellschaft’s BioMarin Pharmaceuticals BMRN Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,389
Closed -$286K – 143
2020
Q1 		$286K Sell
3,389
-4,077
-55% -$351K 0.01% 359
2019
Q4 		$631K Buy
7,466
+241
+3% +$18.2K 0.01% 517
2019
Q3 		$487K Buy
7,225
+1,949
+37% +$150K ﹤0.01% 647
2019
Q2 		$452K Buy
5,276
+586
+12% +$50.1K ﹤0.01% 761
2019
Q1 		$417K Buy
4,690
+279
+6% +$25.9K ﹤0.01% 656
2018
Q4 		$376K Sell
4,411
-259
-6% -$24.6K ﹤0.01% 723
2018
Q3 		$453K Sell
4,670
-4,755
-50% -$475K ﹤0.01% 708
2018
Q2 		$888K Sell
9,425
-1,359
-13% -$119K 0.01% 554
2018
Q1 		$874K Buy
10,784
+3,739
+53% +$321K 0.01% 563
2017
Q4 		$628K Buy
7,045
+4,175
+145% +$363K 0.01% 622
2017
Q3 		$267K Sell
2,870
-1,292
-31% -$114K ﹤0.01% 720
2017
Q2 		$378K Sell
4,162
-51,254
-92% -$4.66M 0.01% 565
2017
Q1 		$4.86M Sell
55,416
-64,674
-54% -$5.75M 0.07% 220
2016
Q4 		$9.95M Sell
120,090
-7,957
-6% -$684K 0.15% 131
2016
Q3 		$11.8M Sell
128,047
-49,196
-28% -$4.63M 0.19% 104
2016
Q2 		$13.8K Buy
177,243
+119,149
+205% +$10.1M 0.09% 124
2016
Q1 		$4.79M Sell
58,094
-37,388
-39% -$3.04M 0.04% 245
2015
Q4 		$10M Sell
95,482
-8,913
-9% -$931K 0.08% 187
2015
Q3 		$11M Buy
104,395
+44,016
+73% +$5.88M 0.08% 160
2015
Q2 		$8.26M Sell
60,379
-129,942
-68% -$16.1M 0.04% 249
2015
Q1 		$23.7M Buy
190,321
+4,411
+2% +$467K 0.14% 112
2014
Q4 		$16.8M Buy
185,910
+45,843
+33% +$3.81M 0.11% 161
2014
Q3 		$10.1M Buy
140,067
+80,851
+137% +$5.31M 0.04% 312
2014
Q2 		$3.68M Buy
59,216
+10,029
+20% +$606K 0.02% 555
2014
Q1 		$3.35M Sell
49,187
-35,474
-42% -$2.61M 0.01% 573
2013
Q4 		$5.83M Sell
84,661
-409,763
-83% -$27.8M 0.03% 413
2013
Q3 		$35.7M Buy
494,424
+472,508
+2,156% +$31.4M 0.18% 106
2013
Q2 		$1.22M Buy
+21,916
New +$1.37M 0.01% 885

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Commerzbank Aktiengesellschaft's BMRN Position: Q2 2020 in Review

Commerzbank Aktiengesellschaft sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 3,389 shares — an estimated $286K sold.

Commerzbank Aktiengesellschaft first reported a position in BMRN in Q2 2013 and held it in 28 quarters. The position peaked at $35.7M in Q3 2013. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

  • Commerzbank Aktiengesellschaft reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Commerzbank Aktiengesellschaft sold 3,389 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $286K.
  • Commerzbank Aktiengesellschaft first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 28 quarters.
  • Commerzbank Aktiengesellschaft's BioMarin Pharmaceuticals position peaked at $35.7M in Q3 2013.
  • 527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q2 2020, filed 21 Jul 2020.